Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect
Open Access
- 1 January 2013
- journal article
- Published by Publiverse Online S.R.L in Vascular Cell
- Vol. 5 (1), 1
- https://doi.org/10.1186/2045-824x-5-1
Abstract
Recently, bisphosphonates (BPs) have been widely used in medical practice as anti-resorptive agents owing to their anti-osteoclatic action. In addition, these compounds are also used for their analgesic action and their potential anti-tumour effect. Patients treated with BPs may subsequently develop osteonecrosis of the jaw or maxillary bone after minor local trauma including dental work, recently labelled as bisphosphonate osteonecrosis of jaw (BRONJ). However, the etiopathogenic mechanisms of this pathological condition are poorly understood. Although, several pathways have been proposed for BRONJ occurrence, no single model can explain all morphological changes observed at the macro- and microscopic level. Recent research suggests that BPs may promote an anti-angiogenic effect which contributes directly to the clinical features associated with BRONJ. Remarkably, the anti-angiogenic effect promoting BRONJ might be in keeping with the anti-neoplastic action of BPs. The current review, presents clinical diagnostic criteria. In addition, based on our own experience we describe the histopathological criteria for diagnosis of BRONJ and the possible pathways which may lead to this frustrating pathological condition.Keywords
This publication has 48 references indexed in Scilit:
- Novel Therapy to Reverse the Cellular Effects of Bisphosphonates on Primary Human Oral FibroblastsJournal of Oral and Maxillofacial Surgery, 2011
- Bisphosphonates Inhibit Expression of p63 by Oral KeratinocytesJournal of Dental Research, 2011
- Bisphosphonates Induce Senescence in Normal Human Oral KeratinocytesJournal of Dental Research, 2011
- The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro studyClinical Oral Investigations, 2011
- In vivo effects of zoledronic acid on oral mucosal epithelial cellsOral Diseases, 2010
- Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cellsInternational Journal of Cancer, 2009
- Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administrationCytokine, 2008
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- Bisphosphonates for Treatment and Prevention of Bone MetastasesJournal of Clinical Oncology, 2005
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseThe New England Journal of Medicine, 2005